Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Michael D. Staehler"'
Autor:
Hedyeh Ebrahimi, Dena Battle, Nicholas J. Salgia, Zeynep B. Zengin, Nazli Dizman, Luis Meza, Cristiane D. Bergerot, Regina Barragan-Carrillo, JoAnn Hsu, Daniela Castro, Benjamin Mercier, Neal Chawla, Xiaochen Li, Abhishek Tripathi, Sandy T. Liu, Alex Chehrazi-Raffle, Ulka Vaishampayan, Michael D. Staehler, Sumanta K. Pal
Publikováno v:
Nutrients, Vol 16, Iss 11, p 1630 (2024)
Many patients diagnosed with cancer adopt dietary changes and supplement use, and a growing body of evidence suggests that such modifications can affect outcomes to cancer therapy. We sought to assess the prevalence of these practices and the surroun
Externí odkaz:
https://doaj.org/article/06e6f35dc732492abffa3b9a9898817f
Autor:
Cristiane Decat Bergerot, Dena Battle, Paulo Gustavo Bergerot, Nazli Dizman, Eric Jonasch, Hans J. Hammers, Daniel J. George, Axel Bex, Borje Ljungberg, Sumanta Kumar Pal, Michael D. Staehler
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Despite numerous therapeutic advances in renal cell carcinoma (RCC), little is known about patients' perspectives on cancer care. An international survey was conducted to identify points of frustration associated with cancer care reported by patients
Externí odkaz:
https://doaj.org/article/c6814f842c41413fa719ff6b5d715b23
Autor:
Hedyeh Ebrahimi, Dena Battle, Zeynep Busra Zengin, Nazli Dizman, Luis A Meza, Daniela V. Castro, Ameish Govindarajan, Benjamin D. Mercier, Neal Shiv Chawla, Alex Chehrazi-Raffle, Abhishek Tripathi, Sandy Liu, Ulka N. Vaishampayan, Michael D. Staehler, Sumanta Monty Pal
Publikováno v:
Journal of Clinical Oncology. 41:662-662
662 Background: Mounting data suggests that dietary modification and supplement use, including probiotics, may modulate outcomes with immunotherapy in cancer therapy (Spencer CN et al. Science 2021; Dizman N et al. Nature Medicine 2022). For the firs
Publikováno v:
Journal of Clinical Oncology. 41:663-663
663 Background: Adjuvant treatment with the immune checkpoint inhibitor (CPI) pembrolizumab and the tyrosine kinase inhibitor (TKI) sunitinib are currently standard of care options for patients with high-risk localized renal cell carcinoma (RCC). How
Autor:
Michael D. Staehler, Hedyeh Ebrahimi, Ulka N. Vaishampayan, Severin Rodler, Sumanta Monty Pal, Dena Battle
Publikováno v:
Journal of Clinical Oncology. 41:651-651
651 Background: Combination therapy based on immunotherapy (IO) alone or in combination with oral tyrosine kinase inhibitors (TKI) has become the standard of frontline therapy in metastatic renal cell carcinoma (RCC). We sought to ascertain real worl
Autor:
Ulka N. Vaishampayan, Michael D. Staehler, Sumanta Monty Pal, Emma Zipperer, Neil Vaishampayan, Neha Shah, Dena Battle
Publikováno v:
Journal of Clinical Oncology. 41:640-640
640 Background: Immune based regimen has rapidly become the mainstay of frontline therapy in advanced RCC. The median survival is in the range of 48-55 months and long term remissions are feasible. The impact of the therapy on other health conditions
Autor:
Ebrahimi, Hedyeh, Battle, Dena, Salgia, Nicholas J., Zengin, Zeynep B., Dizman, Nazli, Meza, Luis, Bergerot, Cristiane D., Barragan-Carrillo, Regina, Hsu, JoAnn, Castro, Daniela, Mercier, Benjamin, Chawla, Neal, Li, Xiaochen, Tripathi, Abhishek, Liu, Sandy T., Chehrazi-Raffle, Alex, Vaishampayan, Ulka, Staehler, Michael D., Pal, Sumanta K.
Publikováno v:
Nutrients; Jun2024, Vol. 16 Issue 11, p1630, 12p
Publikováno v:
Immunotherapy Weekly; 6/11/2024, p1041-1041, 1p
Autor:
Staehler, Michael D., Vaishampayan, Ulka, Pal, Sumanta K., Msaouel, Pavlos, Derweesh, Ithaar, Penson, David F., Battle, Dena J.
Publikováno v:
Journal of Urology; 2024 Supplement 5, Vol. 211, pe1220-e1220, 1p
Autor:
Staehler, Michael D., Ivanova, Troya, Blajan, Iulia, Aydogdu, Can, Graser, Annabel, Rodler, Severin
Publikováno v:
Journal of Urology; 2024 Supplement 5, Vol. 211, pe847-e847, 1p